- AstraZeneca Plc AZN has reported topline data from the MESSINA Phase 3 trial Fasenra (benralizumab) in Eosinophilic esophagitis (EoE) patients aged 12 years or older.
- Eosinophilic esophagitis (EoE) is characterized by the abnormal presence of eosinophils, a type of white blood cell, in the inner lining of the esophagus. Patients experience difficulty swallowing (dysphagia), pain, food getting stuck, and anxiety.
- The data showed that Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
- Fasenra demonstrated a statistically significant improvement in histological disease remission but not a change in dysphagia symptoms compared to the placebo.
- The trial included 210 patients who received either Fasenra or a placebo at four-week intervals.
- The safety and tolerability profile for Fasenra in the trial was consistent with the known profile of the medicine.
- Fasenra is currently approved as an add-on maintenance treatment for severe eosinophilic asthma in the U.S., EU, Japan, and other countries and is approved for self-administration in the U.S., EU, and other countries.
- Price Action: AZN shares are up 1.25% at $55.87 during the premarket session on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.